Found: 7
Select item for more details and to access through your institution.
Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.
- Published in:
- Oncogene, 2013, v. 32, n. 8, p. 1066, doi. 10.1038/onc.2012.117
- By:
- Publication type:
- Article
Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
- Published in:
- Leukemia (08876924), 2015, v. 29, n. 4, p. 981, doi. 10.1038/leu.2014.320
- By:
- Publication type:
- Article
Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells.
- Published in:
- Leukemia (08876924), 2011, v. 25, n. 1, p. 89, doi. 10.1038/leu.2010.233
- By:
- Publication type:
- Article
Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.
- Published in:
- Leukemia (08876924), 2008, v. 22, n. 3, p. 585, doi. 10.1038/sj.leu.2405058
- By:
- Publication type:
- Article
Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls.
- Published in:
- Clinical & Experimental Immunology, 2001, v. 126, n. 2, p. 206, doi. 10.1046/j.1365-2249.2001.01635.x
- By:
- Publication type:
- Article
PENTOSE PHOSPHATE PATHWAY INHIBITION ACTIVATES MACROPHAGES TOWARDS PHAGOCYTIC LYMPHOMA CELL CLEARANCE.
- Published in:
- Hematological Oncology, 2023, v. 41, p. 627, doi. 10.1002/hon.3165_476
- By:
- Publication type:
- Article
THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION.
- Published in:
- Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.161_2880
- By:
- Publication type:
- Article